SK
TAK icon

Sarah Ketterer’s Takeda Pharmaceutical TAK Stock Holding History

Sarah Ketterer’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-522,030
Closed -$6.91M – 107
2024
Q4 		$6.91M Sell
522,030
-759,162
-59% -$10.4M 0.16% 71
2024
Q3 		$18.2M Sell
1,281,192
-72,972
-5% -$1.04M 0.45% 52
2024
Q2 		$17.5M Sell
1,354,164
-90,744
-6% -$1.2M 0.48% 54
2024
Q1 		$20.1M Buy
1,444,908
+99,263
+7% +$1.44M 0.52% 51
2023
Q4 		$19.2M Buy
1,345,645
+101,336
+8% +$1.44M 0.49% 52
2023
Q3 		$19.2M Buy
1,244,309
+123,725
+11% +$1.92M 0.51% 50
2023
Q2 		$17.6M Sell
1,120,584
-8,782
-0.8% -$144K 0.46% 49
2023
Q1 		$18.6M Sell
1,129,366
-200,676
-15% -$3.2M 0.45% 46
2022
Q4 		$20.7M Sell
1,330,042
-100,663
-7% -$1.41M 0.6% 40
2022
Q3 		$18.6M Sell
1,430,705
-76,118
-5% -$1.06M 0.52% 45
2022
Q2 		$21.2M Sell
1,506,823
-94,223
-6% -$1.34M 0.53% 44
2022
Q1 		$22.9M Buy
1,601,046
+91,897
+6% +$1.35M 0.55% 41
2021
Q4 		$20.6M Sell
1,509,149
-397,849
-21% -$5.58M 0.45% 47
2021
Q3 		$31.2M Sell
1,906,998
-124,266
-6% -$2.09M 0.7% 40
2021
Q2 		$34.2M Buy
2,031,264
+357,809
+21% +$6.09M 0.7% 43
2021
Q1 		$30.6M Buy
1,673,455
+129,284
+8% +$2.33M 0.6% 42
2020
Q4 		$28.1M Buy
1,544,171
+65,647
+4% +$1.15M 0.53% 45
2020
Q3 		$26.4M Sell
1,478,524
-61,855
-4% -$1.13M 0.49% 43
2020
Q2 		$27.6M Sell
1,540,379
-632,986
-29% -$11.4M 0.5% 42
2020
Q1 		$33M Sell
2,173,365
-328,931
-13% -$5.96M 0.53% 40
2019
Q4 		$49.4M Sell
2,502,296
-26,204
-1% -$501K 0.53% 40
2019
Q3 		$43.5M Sell
2,528,500
-19,240
-0.8% -$333K 0.52% 35
2019
Q2 		$45.1M Buy
2,547,740
+159,387
+7% +$2.9M 0.49% 37
2019
Q1 		$48.7M Buy
2,388,353
+183,969
+8% +$3.7M 0.49% 35
2018
Q4 		$37.1M Buy
+2,204,384
New +$37.2M 0.44% 38

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Sarah Ketterer's TAK Position: Q1 2025 in Review

Sarah Ketterer sold out of Takeda Pharmaceutical (TAK) in Q1 2025, closing a stake of 522,030 shares — an estimated $6.91M sold.

Sarah Ketterer first reported a position in TAK in Q4 2018 and held it in 25 quarters. The position peaked at $49.4M in Q4 2019. 308 funds tracked by Wall St. Rank hold TAK as of Q1 2025.

  • Sarah Ketterer reported no remaining Takeda Pharmaceutical position as of Q1 2025 after selling out during the quarter.
  • Sarah Ketterer sold 522,030 Takeda Pharmaceutical shares in Q1 2025, an estimated $6.91M.
  • Sarah Ketterer first reported a position in Takeda Pharmaceutical in Q4 2018 and held it in 25 quarters.
  • Sarah Ketterer's Takeda Pharmaceutical position peaked at $49.4M in Q4 2019.
  • 308 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2025.

Based on Causeway Capital Management's 13F filing for Q1 2025, filed 14 May 2025.